In MS patients, CXCL12 levels are elevated in serum and cerebrospinal fluid and expressed in active lesions, suggesting its involvement in disease pathology (Azin et al., 2012; Khorramdelazad et al., 2016; Bagheri et al., 2019; Marastoni et al., 2021). This evidence concerns the gene CXCL12 and myeloid sarcoma.